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osting by EAbstract Background: There is a strong correlation between heart rate and myocardial ischemia,
cardiovascular diseases, and life expectancy in general; however, heart rate has been neglected as an
important risk factor as well as a therapeutic opportunity.
Purpose: To investigate the effect of aggressive heart rate reduction (50 6 HR 6 60 bpm) on
anti-ischemic and anti-anginal efﬁcacy, left ventricular function, exercise tolerance and quality of
life in patients with stable coronary artery disease with or without left ventricular dysfunction
during 4 months.
Methods: A total of 159 patients presented with stable CAD without clinical heart failure symp-
toms were included in a open-label, non-comparative, prospective clinical study between June 2009
to February 2010 in King Abdul Aziz Specialist Hospital, Taif, KSA, Al Hayah National Hospital,
Khamis Mushyt, KSA and Critical care department, Cairo University, Egypt. All included patients
were, in addition to the ant ischemic treatment, subjected to aggressive heart rate control starting by
beta blocker titrated to the maximum dose as tolerated, then Ivabradine added if the target heart rate
is not achieved or rate control started by Ivabradine if beta blockers are contraindicated. Exercise
treadmill test (ETT) to assess exercise capacity using time to 1 mm ST-segment depression in milli-
seconds, ejection fraction (EF) assessed by transthoracic echocardiography and frequency of angina66 535744812; fax: +966
oo.com (H.A.E Azeem),
El Khalek), 616@hotmail.
y. Production and hosting by
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68 H.A.E Azeem et al.attacks and the use of sublingual nitroglycerin per week during the last week were evaluated during a
follow-up for 4 months. The patients were divided into two groups, group-I (patients achieved a rest-
ing heart rate between 50 and 60 bpm with heart rate reduction treatment) and group-II (patients
with resting HR >60 bpm in spite of maximum treatment for heart rate reduction).
Results: The resting heart rate was signiﬁcantly reduced from 77.98 ± 8.7 at baseline to
60.68 ± 4.34 bpm after 4 months of treatment, P< 0.001. The frequency of angina pectoris attacks
had been signiﬁcantly reduced from 2.14 ± 1.27 to 0.48 ± 0.58 attacks per week, P< 0.001 and the
highest signiﬁcant reduction was observed with group-I. Also, the frequency of use sublingual nitrate
therapy was signiﬁcantly reduced from 1.38 ± 1.1 tablet per week at the last week before the study to
0.12 ± 0.33 tablet per week during the last week after 4 months of treatment, P< 0.001 and the
reduction was more signiﬁcantly with group-I. Exercise treadmill test demonstrated statistically sig-
niﬁcant increase in the time to 1 mm ST-segment depression from 357.36 ± 66.73 at baseline to
387.96 ± 65.19 ms. after 4 months with P < 0.001. The degree of improvement was signiﬁcantly
higher for group-I (from 358.06 ± 68.81 at baseline to 391.71 ± 69.01 after 4 months with
P< 0.001) than that of group-II (from 356.11 ± 64.8 at baseline to 381.27 ± 59.08 after 4 months
with P< 0.001). Ejection fraction showed a statistically signiﬁcant increase from 59.76 ± 6.86 at
baseline to 61.04 ± 5.35 after 4 months with P< 0.001.
Conclusion: This study indicates that heart rate reduction has been associated with an improvement
in quality of life in patients with stable coronary artery disease, presenting new opportunities for
treatment.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
An increase in pulse rate is the simplest and most effective way
to raise cardiac output in response to an increase in total oxy-
gen requirement. The contraction cycle determines >90% of
myocardial oxygen demand. Heart rate (HR) is, therefore,
an important determinant of myocardial oxygen consumption.
Other important modulators of oxygen consumption per beat
are the inotropic state, or the velocity of contraction, and the
developed wall tension. Resting HR varies between species and
among healthy individuals, and has been shown to be an index
of expected life span (Levine, 1997).
In the Go¨teborg multifactor primary prevention trial,
which included healthy men during a follow-up period of 12
years, total mortality and, in particular, coronary mortality,
were closely related to HR. There was a two- to threefold in-
crease in mortality in subjects with a HR of >90 beats per
minute (bpm) compared with those <60 bpm (Wilhelmsen
et al., 1986). In another study of 7079 men, without ischemic
heart disease and a follow-up period of 23 years, resting HR
was an independent risk factor for sudden death (Jouven
et al., 2001). Moreover, in the Framingham study, HR was di-
rectly related to total mortality, cardiovascular mortality, and
coronary mortality (Gillman et al., 1993).
The relationship between HR and life expectancy is found,
not only in humans, but also in other mammals; this relation-
ship is so strong that the average total heart beats per lifetime
is remarkably constant and has been calculated as 7.3 · 10.
Clearly, increased HR shortens life but it is unknown if HR
reduction in the healthy population prolongs life (Levine,
1997; Gillman et al., 1993).
In patients with coronary artery disease, high resting HR is a
prognostic determinant of cardiovascular risk during and after
an acute event (Hjalmarson et al., 1990). This is supported by
studies in animals, demonstrating that elevated heart rate in-
creases oxygen requirement and shortens the time tomyocardial
dysfunction and necrosis (Shell and Sobel, 1973). Conversely,
reductions inHR confer protection of the ischemicmyocardium(Kjekshus et al., 1981). The same relationship has been observed
in patients with heart failure (Gillman et al., 1993).
Dyslipidemic inﬂammatory conditions and diabetes are
associated with blunting of autonomic control, with enhanced
sympathetic and reduced vagal inﬂuence on the sinus node in
association with a higher cardiovascular risk in these condi-
tions. Particular attention has, therefore, been paid to the
importance of HR as a target for therapy (Sajadieh et al., 2004).
2. Aim of the work
The objectives of this study are to determine the effect of
aggressive HR reduction (50 6 HR 6 60 bpm) on anti-ische-
mic and anti-anginal efﬁcacy, left ventricular function, exercise
tolerance and quality of life in patients with stable coronary ar-
tery disease with or without left ventricular dysfunction during
4 months.3. Patients and methods
3.1. Design
The study between June 2009 to February 2010 in King Abdul
Aziz Specialist Hospital, Taif, KSA, Al Hayah National Hos-
pital, Khamis Mushyt, KSA and Critical care department,
Cairo University, Egypt is a open-label, non-comparative, pro-
spective clinical trial. The study included 159 patients present-
ing with stable coronary artery disease without clinical heart
failure symptoms.
3.2. Ethics
The study protocol was approved by the local Ethics Commit-
tee. This study did not interfere with the current medical prac-
tice of the investigator. No invasive medical procedure is
required by the protocol. The investigator can decide for any
treatment that is for the best interest of his patients.
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3.3.1. Inclusion criteria
(1) Patients older than 18 years, (2) patients from either sex, (3)
out-patients presenting with documented stable coronary ar-
tery disease with or without left ventricular dysfunction, (4)
patients with stable angina >6 months since diagnosis and
(5) resting HR >60 bpm.
Patients who were excluded from the present study included
those who were younger than 18 years of age, presented with
clinical heart failure, i.e. stage III or IV of the New York Heart
Association (NYHA) classiﬁcation, had unstable angina or MI
<6 months, had Arrhythmia or associated condition or those
who are pregnant or lactating.
3.3.1.1. Treatment. Step-by-step target driven strategy, upon
investigator evaluation starting by b-blockers titrated to max-
imum dose as tolerated, then Ivabradine added if target HR is
not achieved or one can start by Ivabradine if b-blockers are
contraindicated. b-Blocker therapy was started in a daily dose
of 25 mg atenolol or 2.5 mg bisoprolol daily. The dose was in-
creased gradually during a follow up period of 2–4 weeks up
to a maximum daily dose of 200 mg atenolol or 10 mg biso-
prolol. Ivabradine was started in a dose of 5 mg, twice daily.
The dose was increased gradually during a follow up period of
2–4 weeks up to a maximum dose of 7.5 mg, twice daily. A
starting reduced dose of 2.5 mg, twice daily was recommended
in patients with age >75 years, in addition to b-blocker if
target HR is achieved or HR continuously <50 bpm during
treatment.3.3.1.2. Assessments
– Visit 1 (week 0): Inclusion visit
1. Patient demographics
2. Cardiovascular risk factors
3. History of cardiovascular events
4. Resting blood pressure and HR:
– Patients should be at rest in sitting position for 5 min
– Systolic and diastolic blood pressure are measured by a
sphygmomanometer
– Resting HR is measured by physical palpation and
counting for one minute
– Resting HR is then measured by an electrocardiogram.
5. Current cardiovascular treatments
6. Frequency of angina attacks and use of sub-lingual (SL)
nitroglycerin per week during the last week.
7. Exercise treadmill test (ETT) to assess exercise capac-
ity using time to 1 mm ST-segment depression in
milliseconds
8. Ejection fraction (EF) by echocardiography: The echo-
cardiography images were obtained using a transducer
3.5 MHz with 2D guided M-mode facilities. All patients
were examined in the partial left lateral decubitus and
were angled according to necessity to obtain optimal
windows for optimal views according to the recommenda-
tions of the American Society of Echocardiography (Sahn
et al., 1978). Patients with non optimum windows were
excluded from the study. Images were obtained in theparasternal long axis, parasternal short axis (mid-level),
apical two and four chamber views. Optimization was
performed using harmonic imaging, gain, dynamic range,
frequency, sector width and focus to improve signal-
to-noise ratio and provide optimal endocardial deﬁnition
and images were accepted for analysis according to the
guide lines proposed by Gordon et al. (1983) when at least
80% of endocardium was seen. Left ventricular end dia-
stolic dimension, left ventricular end systolic dimension
and fraction shortening were assessed by parasternal long
axes view with M-mode technique by placing the curser
just below the tips of the anterior mitral valve leaﬂets cut-
ting perpendicularly the right ventricle, basal interventric-
ular septum and posterior wall. Left ventricular end
diastolic volume, Left ventricular end systolic volume,
FS and ejection fraction were assessed by apical four
chamber and two chamber views with the modiﬁed Simp-
son’s method (Weyman and Doty, 1982). This was per-
formed at both end-diastole and systole. End-diastole
was taken to coincide with the Q-wave on the electrocar-
diogram and end-systole was selected by identifying the
frame with smallest LV cavity cross-sectional area in both
apical views prior tomitral valve opening. The parameters
were averaged from three consecutive measurements.
– Visit 2 (week 4): Follow-up visit 1
1. Resting blood pressure and HR: the same as inclusion
visit
2. Current cardiovascular treatments
3. Frequency of angina episodes and use of SL nitrates dur-
ing the last week
– Visit 3 (after 16 weeks): End of the study
1. Resting blood pressure and HR: the same as before
2. Current cardiovascular treatments
3. Frequency of angina episodes and use of SL nitrates per
week
4. ETT using time to 1 mm ST-segment depression in
milliseconds
5. EF by echocardiography
3.3.1.3. End-points
Primary end-points:
1. Resting HR reduction from baseline
2. Improvement in exercise tolerance parameter by ETT.
Assessment is done for time to 1 mm ST-segment depres-
sion in milliseconds
3. Improvement in EF
Secondary end-points:
1. Decrease of angina episodes and use of SL nitrates
2. Mean change in blood pressure from week 0 to week 12
3. Evolution of the quality of life from week 0 to week 4 and
week 12 by the frequency of angina episodes and use of SL
nitrates
The primary and second end points were analyzed on all
patients who are divided into two groups:
70 H.A.E Azeem et al. Group-I: patients who achieved a resting HR between 50
and 60 bpm after 2–4 weeks of HR reduction treatment.
 Group-II: patients with resting HR >60 bpm in spite of








Long acting nitrates W0 99 55 44
W4 97 54 434. The statistics
Data were collected and veriﬁed prior to analysis, statistical
analyses were performed using SPSS software for windows,
version 18.0 (SPSS Inc., Chicago IL, USA). Continuous data
are presented as mean + SD or median and compared using
student t-test. Differences in the occurrence of angina pectoris
attacks and in the need for the use of sublingual nitrates were
evaluated using the Wilcoxon signed rank test. Categorical
variables were reported as absolute numbers (frequency per-
centages). A P value <0.05 was considered to be signiﬁcant.
5. Results
5.1. Demographic and clinical data of the patients included
Out of 200 patients, only 159 patients completed the protocol of
the study. Ninety nine (62.3%) were male and 60 (37.7%) were
female, with mean age 56.7 ± 11.4 years. Forty one patients
did not complete the study protocol because of non optimum
echocardiographic window (n= 14), incompliance of the pa-
tient (n= 9), the fact that the patient was symptom free and
the patient terminated his or her therapy independently
(n= 18).
Mean systolic blood pressure was lowered from
137.04 ± 13.12 to 129.72 ± 6.62 mmHg (P< 0.001) between
baseline and the fourth month of treatment with beta block-
er ± other antihypertensive drugs. Also, mean diastolic blood
pressure was lowered from 85.7 ± 8.73 to 80.44 ± 5.8 mmHg
(P< 0.001).Table 1 Demographic and clinical data of patients entered
into the study.
Characteristics Value
Age: (mean ± SD in years (Range)) 56.7 ± 11.4 (39–77)
Male:Female sex (No. of patients ratio) 99:60 (1.65)
CCS classiﬁcation (Campeau, 1976) (No. of patients (%))
Geade I 45 (28.3%)
Geade II 59 (37.1%)
Geade III 47 (29.6%)
Geade IV 8 (5%)
Concomitant disease
Hypertension 84 (52.8%)





Family history 68 (42.7%)
Smoker 55 (34.6%)
Bronchial asthma 10 (6.3%)
Chronic obstructive air way disease 26 (16.3%)
Cerebrovascular disease 8 (5%)
Hyperthyroidism 3 (1.9%)The Canadian Cardiovascular Society (CCS) classiﬁcation
of angina pectoris of the patients is given in Table 1 (Campeau,
1976).
Calcium channel blocker was given as adjunctive to control
the hypertension and not used as line of rate control. Rate con-
trol achieved only by b-blocker ± Ivabradine (Table 2).
5.2. Heart rate and ECG parameters
The resting HR was signiﬁcantly reduced from 77.98 ± 8.7
(65–102) at baseline to 60.68 ± 4.34 (54–74) bpm at the third
visit after 4 months of treatment, P value <0.001 (Fig. 1). The
magnitude of reduction of HR was signiﬁcantly higher with
group-I than the reduction of group-II (Table 3).
No relevant changes were observed in ECG parameters, for
example, PR, QRS and QTc periods. Marked physiological
changes were only observed in R–R interval and in the uncor-
rected QT associated with the reduction of HR.
5.3. Angina pectoris and nitrate consumption
Out of the 159 patients, 147 (92.5%) patients had a minimum
of one angina pectoris attack per week during the last week
before the start of the study. At the follow-up after 4 months
of anti-ischemic treatment including HR lowering drugs, the
frequency of angina pectoris attacks had been signiﬁcantly
reduced.(2.14 ± 1.27 (0–5) to 0.48 ± 0.58 (0–2) attacks perW16 97 54 43
Anti platelet W0 158 96 62
W4 159 96 63
W16 159 96 63
ACE-I W0 38 24 14
W4 45 25 20
W16 45 25 20
AT-II antagonist W0 49 29 20
W4 49 29 20
W16 49 29 20
CCB W0 45 21 24
W4 45 21 24
W16 45 21 24
Statin W0 95 60 35
W4 105 63 42
W16 105 63 42
b-blocker W0 102 82 21
W4 62 52 10
W16 50 40 10
Ivabradine W0 30 6 24
W4 36 6 30
W16 36 6 30
b-blocker + Ivabradine W0 27 15 12
W4 61 33 27
W16 73 42 31
ACE-I, angiotensin converting enzyme inhibitor; CCB, calcium
channel blocker; AT-II antagonist, angiotensin II antagonist; W,
week.
Figure 1 Heart rate trend of the patents.
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served with group I (0.28 ± 0.45 (0–1) attack per week).
Also, the frequency of use sublingual nitrate therapy was
signiﬁcantly reduced from 1.38 ± 1.1 (0–4) tablet per week
at the last week before the study to 0.12 ± 0.33 (0–1) tablet
per week during the last week after 4 months of treatment,
P< 0.001. The reduction was more signiﬁcantly with group-
I 0.04 ± 0.17 tablet per week.
5.4. Exercise tolerance and EF
Our study revealed that exercise tolerance assessed by exercise
treadmill test showed a statistically signiﬁcant increase in the
time to 1 mm ST-segment depression after 4 months of anti-
ischemic treatment including rate control drugs from
357.36 ± 66.73 (236–466) at baseline to 387.96 ± 65.19
(269–487) ms. after 4 months with P< 0.001. The degree of
improvement was signiﬁcantly higher for group-I (from
358.06 ± 68.81 at baseline to 391.71 ± 69.01 after 4 months
with P< 0.001) than that of group-II (from 356.11 ± 64.8
at baseline to 381.27 ± 59.08 after 4 months with P< 0.001).
Ejection fraction assessed by transthoracic echocardiogra-
phy showed a statistically signiﬁcant increase after 4 monthsTable 3 Clinical outcome of patients included into the study.
Time Total
HR WO 77.98 ± 8.71
W16 60.68 ± 4.34
P value <0.001
Frequency of angina WO 2.14 ± 1.27
W16 0.48 ± 0.58
P value <0.001
Frequency of SLN WO 1.38 ± 1.10
W16 0.12 ± 0.32
P value <0.001
ETT (ms) WO 357.36 ± 66.73
W16 387.96 ± 65.19
P value <0.001
EF (%) WO 59.76 ± 6.86
W16 61.04 ± 5.35
P value <0.001
HR, heart rate; SLN, sublingual nitrate; ETT, Exercise treadmill test;
P= 0.05.of treatment (from 59.76 ± 6.86 at baseline to 61.04 ± 5.35
after 4 months with P< 0.001). The degree of increase was
non signiﬁcantly higher for group-I (from 59.96 ± 6.84 at
baseline to 61.09 ± 5.03 after 4 months) than that of group-
II (from 59.38 ± 7.07 at baseline to 60.94 ± 6.03 after 4
months).
6. Discussion
The rate of sinus rhythm, or HR, is one of the most easily mea-
sured basic physiological characteristics. Resting HR is known
to be an independent risk factor associated with overall and
cardiovascular mortality in the general population, as well as
in patients with arterial hypertension, metabolic syndrome,
and coronary artery disease. Therefore HR has attracted the
growing attention of researchers because of its re-endorsed
prognostic signiﬁcance and new therapeutic opportunities for
its control (Levine, 1997; Benetos et al., 1999; Hozawa et al.,
2004).
For this reason, our study was conducted in order to
determine the effect of aggressive HR reduction (50 6
HR 6 60 bpm) on anti-ischemic and anti-anginal efﬁcacy, left
ventricular function, exercise tolerance and quality of life in
patients with stable coronary artery disease with or without
left ventricular dysfunction during 4 months of follow-up.
We demonstrate that resting HR was signiﬁcantly reduced
from 77.98 ± 8.7 to 60.68 ± 4.34 bpm, P< 0.001 between
baseline and the third visit after 4 months of anti ischemic
treatment including HR lowering drugs. b-Blockers (except
those with sympathomimetic effect) are used as ﬁrst line phar-
macologic treatment for heart rate reduction; the dose was ad-
justed to secure a resting HR 660 bpm. In some patients,
therapy with b-blocker was limited by side effects such as
chronic asthma, obstructive airway disease, hypotension and
non adequate response, preventing appropriate HR reduction,
making the use of other rate lowering drug; sinus node inhib-
itor, as adjunctive or alternative treatment.
Sinus node inhibitor, Ivabradine, is a selective bradycardiac
agent approved for clinical use in patients with stable angina.
It reduces the ﬁring rate of the pacemaker cells in the sinoatrial
node at rest and exercise by blocking If ion channels on theGroup I Group II LSD at 0.05
73.93 ± 6.99 85.16 ± 6.64
57.87 ± 1.69 65.66 ± 2.80
<0.001 <0.001
1.87 ± 1.23 2.61 ± 1.24 0.37
0.28 ± 0.45 0.83 ± 0.62
<0.001 <0.001
1.06 ± 0.94 1.94 ± 1.16 0.29
0.03 ± 0.17 0.27 ± 0.46
<0.001 <0.001
358.06 ± 68.81 356.11 ± 64.8 25.67
391.71 ± 69.01 381.27 ± 59.08
<0.001 <0.001
59.96 ± 6.84 59.38 ± 7.07 14.68
61.09 ± 5.03 60.94 ± 6.03
0.032 0.003
EF, ejection fraction; W, week; LSD, least signiﬁcant difference at
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stolic current. The If current, activated by hyperpolarization
and modulated by the autonomic nervous system, drives the
slow diastolic depolarization, which in turn determines the rate
of pacemaker activity. Ivabradine does not decrease myocar-
dial contractility or affect the cardiac conduction system or
ventricular repolarization. In contrast to b-blockers, no re-
bound effects with drug cessation or pharmacological toler-
ance with long-term use have been observed following
treatment with Ivabradine (DiFrancesco and Camm, 2004).
Because of the negative inotropic effect and effect on atrio-
ventricular conduction, which is ampliﬁed in the presence of b-
blocker; the ﬁrst rate lowering line of treatment in this study,
especially in patients with left ventricular dysfunction, HR
lowering calcium channel antagonists (nondihydropyridine
calcium channel antagonists) were not used in this study.
Other classes’ calcium channel antagonists used only as
adjunctive line to the other antihypertensive drugs only.
We also demonstrate that the frequency of angina pectoris
attacks and the use of sublingual nitrate therapy had been
signiﬁcantly reduced, P< 0.001 for both and the highest
signiﬁcant reduction were observed with group-I.
In concordance with this result, Koster et al., 2009, in
which 4954 patients with stable angina pectoris received Ivabr-
adine either alone or in combination with b-blocker were fol-
lowed for 4 months, demonstrated that angina pectoris
attacks were reduced from 2.4 ± 3.1 to 0.4 ± 1.5 per week
(P< 0.0001) and consumption of short acting nitrates was re-
duced from 3.3 ± 4.4 to 0.6 ± 1.6 per week (P< 0.0001).
In addition, The Coronary Artery Surgery Study (CASS)
registry, in which 25,000 patients were followed for 15 years,
found that the overall and cardiovascular mortality and car-
diovascular morbidity and hospitalizations were increased
with increasing heart rate (Diaz et al., 2005).
Also, other studies in post myocardial infarction and heart
failure patients have demonstrated clear beneﬁts of treatment
with HR lowering drugs with regard to morbidity and mortal-
ity (Kjekshus, 1986, The Cardiac Insufﬁciency Bisoprolol
Study II CIBIS-II, 1999; Gullestad et al., 2005; Borer et al.,
2003; Tardif et al., 2005).
Stable angina is secondary to increased metabolic demands
in the presence of signiﬁcant coronary artery stenosis. The det-
rimental effect of a HR increase may be related to several
mechanisms, including an increase in oxygen consumption
and the workload of the heart, precipitating ischemia and
thereby amplifying the risk of a cardiac event. Most ischemia
during daily life is associated with signiﬁcant increases in
HR. Also, evidence suggests that tachycardia is associated with
increased sympathetic activity and reduced vagal activity. Ani-
mal studies show that high heart rates promote atherogenesis,
and that this process may be slowed by HR reduction,
achieved with surgical ablation of the sinoatrial node. There
is also a relationship between mean HR and the genesis of pre-
mature ventricular contractions, which is characterized by an
increase in the number of tachycardia-enhanced arrhythmias.
In addition, increased sympathetic activity and low vagal tone
may reduce the threshold for ventricular ﬁbrillation. A fast HR
is also associated with coronary plaque disruption (Purcell,
1999; Heidland and Strauer, 2001).
It has also recently been shown that increased HR (and re-
duced HR variability) are associated with raised C-reactive
protein concentration and white cell count, in healthy mid-dle-aged subjects. This subclinical inﬂammation, coupled with
an autonomic imbalance, may be closely linked to atheroscle-
rotic plaque disruption and increased mortality risk (Sajadieh
et al., 2004; Purcell, 1999; Heidland and Strauer, 2001).
Conversely, HR reduction in ischemia directly reduces myo-
cardial oxygen demand; prolongation of diastole, caused by a
reduction in HR, may increase perfusion to injured myocar-
dium, particularly to the subendocardium, preventing plaque
rupture, protecting the ischemic myocardium, and maintaining
cardiac contractility (Heidland and Strauer, 2001).
We also demonstrated that, exercise tolerance assessed by
exercise treadmill test showed a statistically signiﬁcant increase
in the time to 1 mm ST-segment depression after 4 months of
anti-ischemic treatment including rate control drugs and the
degree of improvement was signiﬁcantly higher for group-I
than that of group-II. Also, ejection fraction showed a statisti-
cally signiﬁcant increase after 4 months of treatment. The de-
gree of increase was non signiﬁcantly higher for group-I than
that of group-II.
These observations are in agreement with a randomized,
double blind study, International Trial of Treatment of the
anti-anginal with Ivabradine compaired to atenolol (INTIA-
TIVE), which compared Ivabradine with atenolol over 4
months in 939 patients with stable angina pectoris and docu-
mented coronary artery disease. Patients received either Ivabr-
adine 5 mg bid for 4 weeks, increased to 7.5 mg bid for a
further 3 months, or atenolol 50 mg daily for 4 weeks, in-
creased to 100 mg daily for a further 3 months. At 4 months,
total exercise duration on a treadmill ETT, at lowest treatment
activity, increased by 86 s with Ivabradine 7.5 mg and 78 s with
atenolol 100 mg (Tardif et al., 2005).7. Conclusion
Heart rate reduction is clinically feasible and can effectively
improve quality of life in patients with stable coronary heart
disease. Thus, it seems sensible to reduce both heart rate and
the demands for myocardial oxygen consumption in patients
with coronary artery disease.References
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